Literature DB >> 2551498

Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.

W Schlechte1, G Murano, D Boyd.   

Abstract

The relevance of urokinase receptors to urokinase-mediated laminin degradation was investigated in cultured colon cancer. Six colon cancer cell lines degraded laminin in a plasminogen-dependent manner. The ability of the individual cell lines to cleave the glycoprotein correlated well (r2 = 0.9242) with the amount of urokinase recovered from the cell surface by a mild acid treatment. A radioreceptor assay indicated that colon cancer cells most active in degrading the laminin, possessed the largest number of urokinase receptors. Moreover, acid treatment which depletes the receptors of endogenous plasminogen activator augmented the specific binding of radioactive urokinase to the colon cancer cells by 12-200%. A cell line (HCT 116) which displayed 1.1 x 10(5) receptors/cell the majority of which were occupied with endogenous urokinase was selected and the effects of a urokinase receptor antagonist on laminin degradation determined. The peptide antagonist reduced laminin turnover by 60-80%. Morphological observations were consistent with these findings. Plasminogen-treated HCT 116 cells retracted from the culture dish and many cells were observed in the culture medium. This effect could be largely reversed by simultaneous treatment with the peptide antagonist. A poor correlation was found between laminin degradation and soluble urokinase (r2 = 0.1074). These data strongly argue for a role of the urokinase receptor in facilitating the action of the plasminogen activator in colon cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 2.  Cell-matrix interactions during tumor invasion.

Authors:  J R Starkey
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

3.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

Review 4.  Cathepsin B and other proteases in human colorectal carcinoma.

Authors:  J M Jessup
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

5.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Authors:  U Reuning; O Wilhelm; T Nishiguchi; L Guerrini; F Blasi; H Graeff; M Schmitt
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

6.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 7.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec

8.  The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.

Authors:  Jun Sato; Jeffrey Schorey; Victoria A Ploplis; Erijka Haalboom; Liana Krahule; Francis J Castellino
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

9.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Authors:  Heng Wang; John Hicks; Parham Khanbolooki; Sun-Jin Kim; Chunhong Yan; Yao Wang; Douglas Boyd
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

10.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Authors:  F Jänicke; M Schmitt; L Pache; K Ulm; N Harbeck; H Höfler; H Graeff
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.